Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France

Roux, Pierre‐Yves Le; Pelletier‐Galarneau, Matthieu; Laroche, Romain; Hofman, Michael S; Zuckier, Lionel S.; Roach, Paul; Vuillez, Jean-Philippe J; Hicks, Rodney J.; Gal, Grégoire Le; Salaun, Pierre–Yves

doi:10.2967/jnumed.115.157743

Cited by 41 publications

(37 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several of those agents are under clinical investigation [26-32]. Recently we reported the synthesis and preliminary evaluation of a PSMA-targeted Lys-Glu urea based theranostic agent YC-9 for prostate cancer optical imaging and PDT [33]. Here we report in more detail the synthesis of this agent and its in vitro and in vivo evaluation for PDT.…”

Section: Introductionmentioning

confidence: 99%

A PSMA-targeted theranostic agent for photodynamic therapy

Chen

Chatterjee

Lisok

et al. 2017

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is over-expressed in the epithelium of prostate cancer and in the neovasculature of many non-prostate solid tumors. PSMA has been increasingly used as a target for cancer imaging and therapy. Here we describe a low-molecular-weight theranostic photosensitizer, YC-9, for PSMA-targeted optical imaging and photodynamic therapy (PDT). YC-9 was synthesized by conjugating IRDye700DX N-hydroxysuccinimide (NHS) ester with a PSMA targeting Lys-Glu urea through a lysine-suberate linker in suitable yield. Optical imaging in vivo demonstrated PSMA-specific tumor uptake of YC-9 with rapid clearance from non-target tissues. PSMA-specific cell kill was demonstrated with YC-9 in vitro through PDT in PSMA+ PC3-PIP and PSMA- PC3-flu cells. In vivo PDT in mice bearing PSMA+ PC3-PIP tumors at 4 h post-injection of YC-9 (A total of four PDT sessions were performed, 48 h apart) resulted in significant tumor growth delay, while tumors in control groups continued to grow. PDT with YC-9 significantly increased the median survival of the PSMA+ PC3-PIP tumor mice (56.5 days) compared to other control groups [23.5-30.0 days, including untreated, light alone, YC-9 alone (without light) and non-targeted IRDye700DX PDT treatment groups], without noticeable toxicity at the doses used. This study proves in principle that YC-9 is a promising therapeutic agent for targeted PDT of PSMA-expressing tissues, such as prostate tumors and may also be useful against non-prostate tumors by virtue of neovascular PSMA expression.

show abstract

Section: Introductionmentioning

confidence: 99%

A PSMA-targeted theranostic agent for photodynamic therapy

Chen

Chatterjee

Lisok

et al. 2017

Journal of Photochemistry and Photobiology B: Biology

View full text Add to dashboard Cite

show abstract

“…The field of nuclear medicine technology, as well as the V/Q study, has evolved greatly over the past 50 y (15). Despite this evolution, V/Q imaging in most facilities is still being performed using technology and techniques similar to those of 25 y ago, and PIOPED-the landmark accuracy study for V/Q imaging-uses mostly planar data (13)(14)(15). However, some investigators believe the technology and agents for V/Q imaging have evolved rapidly in recent years (15).…”

Section: Spect and Spect/ct Studiesmentioning

confidence: 99%

“…Despite this evolution, V/Q imaging in most facilities is still being performed using technology and techniques similar to those of 25 y ago, and PIOPED-the landmark accuracy study for V/Q imaging-uses mostly planar data (13)(14)(15). However, some investigators believe the technology and agents for V/Q imaging have evolved rapidly in recent years (15). Le Roux et al and others have suggested that this evolution in technology has improved the diagnostic performance of SPECT V/Q imaging, with a decrease in the number of nondiagnostic procedures.…”

Section: Spect and Spect/ct Studiesmentioning

confidence: 99%

“…Le Roux et al and others have suggested that this evolution in technology has improved the diagnostic performance of SPECT V/Q imaging, with a decrease in the number of nondiagnostic procedures. Furthermore, SPECT has replaced planar imaging for the diagnosis of PE in Australia, Canada, and France (8,15,16). Several studies have shown that in SPECT/CT V/Q imaging, not only is the specificity and overall diagnostic accuracy of the V/Q study improved, but the ventilation aerosol SPECT/CT study also adds practical clinical information when combined with a perfusion SPECT study (9,15,16).…”

Section: Spect and Spect/ct Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The Importance of Quality in Ventilation–Perfusion Imaging

Mann

DiDea

Fournier³

et al. 2018

J. Nucl. Med. Technol.

View full text Add to dashboard Cite

As the health care environment continues to change and morph into a system focusing on increased quality and evidence-based outcomes, nuclear medicine technologists must be reminded that they play a critical role in achieving high-quality, interpretable images used to drive patient care, treatment, and best possible outcomes. A survey performed by the Quality Committee of the Society of Nuclear Medicine and Molecular Imaging Technologist Section demonstrated that a clear knowledge gap exists among technologists regarding their understanding of quality, how it is measured, and how it should be achieved by all practicing technologists regardless of role and education level. Understanding of these areas within health care, in conjunction with the growing emphasis on evidence-based outcomes, quality measures, and patient satisfaction, will ultimately elevate the role of nuclear medicine technologists today and into the future. The nuclear medicine role now requires technologists to demonstrate patient assessment skills, practice safety procedures with regard to staff and patients, provide patient education and instruction, and provide physicians with information to assist with the interpretation and outcome of the study. In addition, the technologist must be able to evaluate images by performing technical analysis, knowing the demonstrated anatomy and pathophysiology, and assessing overall quality. Technologists must also be able to triage and understand the disease processes being evaluated and how nuclear medicine diagnostic studies may drive care and treatment. Therefore, it is imperative that nuclear medicine technologists understand their role in the achievement of a high-quality, interpretable study by applying quality principles and understanding and using imaging techniques beyond just basic protocols for every type of disease or system being imaged. This article focuses on quality considerations related to ventilation-perfusion imaging. It provides insight on appropriate imaging techniques and protocols, true imaging variants and tracer distributions versus artifacts that may result in a lower-quality or misinterpreted study, and the use of SPECT and SPECT/CT as an alternative providing a high-quality, interpretable study with better diagnostic accuracy and fewer nondiagnostic procedures than historical planar imaging.

show abstract

“…Further, another study with a larger cohort is difficult to generalise because it relies on the acquisition of CT on another device and uses 81m krypton (Kr), a ventilation agent that is expensive, and hence, not widely used. Consequently, it is unsurprising that there is no consensus on the use of hybrid lung SPECT/CT in clinical settings; partly, this could reflect concerns about cost and radiation exposure, but the lack of specific recommendations from professional bodies on whether hybrid SPECT/CT should be employed routinely, selectively or not at all, undoubtedly contributes. Therefore, there is a clear need to evaluate hybrid SPECT/CT using equipment and radiopharmaceuticals that reflect common clinical practices.…”

Section: Introductionmentioning

confidence: 99%

Radionuclide lung scans for suspected acute pulmonary embolism: Single photon emission computed tomography (SPECT) or hybrid SPECT/CT?

Liu

Larcos

2019

J Med Imag Rad Onc

View full text Add to dashboard Cite

Introduction Hybrid single photon emission computed tomography (SPECT) with CT (SPECT/CT) may improve diagnostic accuracy in suspected acute pulmonary embolism, but further research is needed. We evaluated whether the use of attenuation correction and/or the depiction of lung pathology with hybrid SPECT/CT could significantly reduce potentially false‐positive ventilation–perfusion (VQ) SPECT studies or obviate the need for a ventilation study. Methods Two specialists (S1 and S2) reviewed prospectively acquired VQ SPECT/CT in 165 patients. Studies were reported using standard criteria and compared to VQ SPECT and Q SPECT/CT. Results S1 and S2 recorded positive VQ SPECT in 54 (32.7%) and 42 (25.6%) cases, respectively. Hybrid SPECT/CT showed non‐embolic pathology in 41 (S1) and 46 (S2) patients, but compared to VQ SPECT, neither hybrid SPECT/CT nor attenuation correction SPECT/CT had significantly fewer positive studies. Intra‐observer agreement with VQ SPECT/CT was almost perfect (k = 0.91 for S1 and k = 0.95 for S2; P < 0.001), but not with Q SPECT/CT (k = 0.4 for S1 and k = 0.62 for S2; P < 0.001). Inter‐observer agreement was moderate for VQ SPECT (k = 0.65) and VQ SPECT/CT (k = 0.63). Conclusion In our study, hybrid VQ SPECT/CT did not reduce the number of potentially false‐positive VQ SPECT, nor did the CT obviate the need for a ventilation study. Thus, the routine use of hybrid SPECT/CT for suspected pulmonary embolism is not justified.

show abstract

Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France

Cited by 41 publications

References 39 publications

A PSMA-targeted theranostic agent for photodynamic therapy

A PSMA-targeted theranostic agent for photodynamic therapy

The Importance of Quality in Ventilation–Perfusion Imaging

Radionuclide lung scans for suspected acute pulmonary embolism: Single photon emission computed tomography (SPECT) or hybrid SPECT/CT?

Contact Info

Product

Resources

About